The comparative study of quality of life and toxicities in patients with chronic myeloid leukemia during imatinib therapy vs. nilotinib therapy.
Phase of Trial: Phase III
Latest Information Update: 21 May 2012
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 21 May 2012 Planned end date (May 2021) added as reported by Chinese Clinical Trial Register.
- 14 Nov 2011 New trial record